Russia has given regulatory approval to a second Covid-19 vaccine, named ‘EpiVacCorona’, after early-stage studies. The new coronavirus vaccine comes two months after a similar move for Russia’s first vaccine Sputnik V prompted widespread criticism from scientists both at home and abroad.

Coronavirus pandemic: New COVID-19 vaccine developed by Russia's vector institute

Coronavirus Pandemic: Russia registers new COVID-19 vaccine as cases hit record high

Russian journalists working for two state-owned media outlets are among the first to be offered the new Sputnik V COVID-19 vaccine outside of the framework of a clinical trial.

The measure comes after&nbsp;Russian Deputy Communications Minister Alexei Volin noted that&nbsp;journalists are a part of&nbsp;a ''high risk group'' that are contracting the novel virus.

Russia&nbsp;began vaccinating members of the general public seen at high risk of coronavirus infection earlier this month, while separately launching a large-scale trial. So far about 400 people have received the jabs under that scheme, the health ministry said this week.

Also see:&nbsp;<a href="https://www.wionews.com/photos/all-you-want-to-know-about-russias-coronavirus-vaccine-sputnik-v-319775">All you want to know about Russia's coronavirus vaccine 'Sputnik V'</a>

The government last month published a list of jobs considered high risk, which included health workers, journalists and teachers.

With hundreds of potential COVID-19 vaccines in various stages of development around the world,&nbsp;Russia&nbsp;was the first country to license its vaccine for public use and alongside China has been deploying the shots before full efficacy trials are complete.

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/russias-second-covid-19-vaccine-trials-complete-epivaccorona-331610/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

Also see:&nbsp;<a href="https://www.wionews.com/photos/after-russia-these-covid-19-vaccines-set-to-unveil-soon-319760">After Russia, these COVID-19 vaccines set to unveil soon!</a>

Two journalists at the state-run RIA news agency and two at the&nbsp;Russian state television holding company VGTRK, which operates&nbsp;Russia-1 and&nbsp;Russia-24 news channels, said they had been offered a COVID-19 shot on a voluntary basis.

One of the RIA journalists said his impression was that the majority of his colleagues had declined the offer. One of the VGTRK journalists also said many of his colleagues declined.

The RIA news agency confirmed the inoculation program. "We granted employees who constantly work from the office (not remotely), at events, and in the field, the option to receive a Sputnik V vaccination," it said in a statement.

RIA did not say how many employees received the vaccine and VGTRK did not respond to a request for comment. Both companies employ hundreds of people.

At RIA and VGTRK headquarters in Moscow, media workers who spoke to Reuters said they had a basic medical check-up and coronavirus PCR and antibody tests.

In an interview, the chief scientist behind the vaccine's development said people vaccinated outside of a trial undergo a less rigorous medical examination, though they can submit additional health data via an online platform.

At the time of its registration, the vaccine had been tested officially on fewer than 100 volunteers as part of early-stage clinical trials. Late stage trials began last month, with the first volunteer of a 40,000-strong cohort vaccinated on September&nbsp;9.

Russian journalists working for two state-owned media outlets are among the first to be offered the new Sputnik V COVID-19 vaccine outside of the framework of a clinical trial.

Russian journalists working for two state-owned media outlets are among the first to be offered the new Sputnik V COVID-19 vaccine outside of the framework of a clinical trial. The measure comes after Russian Deputy Communications Minister Alexei Volin noted that journalists are a part of a ''high risk group'' that are contracting the novel virus. Russia began vaccinating members of the general public seen at high risk of coronavirus infection earlier this month, while separately launching a large-scale trial. So far about 400 people have received the jabs under that scheme, the health ministry said this week. Also see: All you want to know about Russia's coronavirus vaccine 'Sputnik V' The government last month published a list of jobs considered high risk, which included health workers, journalists and teachers. With hundreds of potential COVID-19 vaccines in various stages of development around the world, Russia was the first country to license its vaccine for public use and alongside China has been deploying the shots before full efficacy trials are complete. Also see: After Russia, these COVID-19 vaccines set to unveil soon! Two journalists at the state-run RIA news agency and two at the Russian state television holding company VGTRK, which operates Russia-1 and Russia-24 news channels, said they had been offered a COVID-19 shot on a voluntary basis. One of the RIA journalists said his impression was that the majority of his colleagues had declined the offer. One of the VGTRK journalists also said many of his colleagues declined. The RIA news agency confirmed the inoculation program. "We granted employees who constantly work from the office (not remotely), at events, and in the field, the option to receive a Sputnik V vaccination," it said in a statement. RIA did not say how many employees received the vaccine and VGTRK did not respond to a request for comment. Both companies employ hundreds of people. At RIA and VGTRK headquarters in Moscow, media workers who spoke to Reuters said they had a basic medical check-up and coronavirus PCR and antibody tests. In an interview, the chief scientist behind the vaccine's development said people vaccinated outside of a trial undergo a less rigorous medical examination, though they can submit additional health data via an online platform. At the time of its registration, the vaccine had been tested officially on fewer than 100 volunteers as part of early-stage clinical trials. Late stage trials began last month, with the first volunteer of a 40,000-strong cohort vaccinated on September 9.

Russian state journalists among first to receive Sputnik V vaccine

Russia's deputy Prime Minister Tatiana Golikova said that the country is preparing to approve a second vaccine 'EpiVacCorona' against the novel coronavirus by October 15.

Russia's second COVID-19 vaccine trials complete | 'Epivaccorona'

Russia expects to register a second potential vaccine against COVID-19 by October 15. Vaccine has been named as 'Epivaccorona'.

COVID-19: Russia completes clinical trials of second vaccine

Russia's deputy Prime Minister Tatiana Golikova on Wednesday said that the country is preparing to approve a second vaccine 'EpiVacCorona' against the novel coronavirus in late September or early October.

Russia's deputy Prime Minister Tatiana Golikova on Wednesday said that the country is preparing to approve a second vaccine 'EpiVacCorona' against the novel coronavirus in late September or early October. Also read: Women may mount stronger COVID-19 immune response During the televised government meet, Golikova told Russian President Vladimir Putin that the vaccine developed by the Vector virology institute will complete its early-stage clinical trials in Siberia by the end of September. “As of today there have been no complications among those vaccinated in the first and second stages of testing,” she said. Also read: Chemical present in insect spray can kill coronavirus: Study Earlier this month, Russia became the first country to grant regulatory approval to a COVID-19 vaccine after less than two months of human testing. This vaccine was called "Sputnik V", to pay their homage to the world’s first satellite launched by the Soviet Union. The Russian authorities have hailed "Sputnik V" safe and effective. However, the experts in the west have been doubtful of the vaccine and have warned against its use until all internationally approved testing and regulatory steps have been taken. According to RDIF, Russia’s sovereign wealth fund, the final phase of clinical trials on “Sputnik V” were beginning. It said 40,000 people would take part in the final trials and that similar trials would also be carried out in five other countries. (Inputs from Reuters)

'EpiVacCorona': Now, Russia readies approval for second COVID-19 vaccine

epivaccorona

Epivaccorona, News on Epivaccorona, stories on Epivaccorona, articles on Epivaccorona, Epivaccorona stories at Wion, Epivaccorona news, Epivaccorona latest news